Gemtuzumab: time to bring back on the market?
Division of Hematology & Medical Oncology, Mayo Clinic Cancer Center, Jacksonville, Florida.
James M
JM
Foran
D000617:Aminoglycosides / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D000079982:Gemtuzumab; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D012106:Research; D056737:Safety-Based Drug Withdrawals; D016896:Treatment Outcome
D000617:Aminoglycosides; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000079982:Gemtuzumab